|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Larici AR, Farchione A, Franchi P,
Ciliberto M, Cicchetti G, Calandriello L, Del Ciello A and Bonomo
L: Lung nodules: Size still matters. Eur Respir Rev. 26:1700252017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Groome PA, Bolejack V, Crowley JJ, Kennedy
C, Krasnik M, Sobin LH and Goldstraw P; IASLC International Staging
Committee; Cancer Research and Biostatistics; Observers to the
Committee; Participating Institutions: The IASLC lung cancer
staging project: Validation of the proposals for revision of the T,
N, and M descriptors and consequent stage groupings in the
forthcoming (seventh) edition of the TNM classification of
malignant tumours. J Thorac Oncol. 2:694–705. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Viswanathan VS, Toro P, Corredor G,
Mukhopadhyay S and Madabhushi A: The state of the art for
artificial intelligence in lung digital pathology. J Pathol.
257:413–429. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pei Q, Luo Y, Chen Y, Li J, Xie D and Ye
T: Artificial intelligence in clinical applications for lung
cancer: Diagnosis, treatment and prognosis. Clin Chem Lab Med.
60:1974–1983. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim TJ, Kim CH, Lee HY, Chung MJ, Shin SH,
Lee KJ and Lee KS: Management of incidental pulmonary nodules:
Current strategies and future perspectives. Expert Rev Respir Med.
14:173–194. 2020. View Article : Google Scholar
|
|
7
|
Ali K and Bal S: Management of Solitary
Pulmonary Nodule. Recent concepts in minimal access surgery. Sharma
D and Hazrah P: 1. Springer Singapore; Singapore: pp. 401–418.
2022, View Article : Google Scholar
|
|
8
|
Hasan N, Kumar R and Kavuru MS: Lung
cancer screening beyond low-dose computed tomography: The role of
novel biomarkers. Lung. 192:639–648. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nooreldeen R and Bach H: Current and
future development in lung cancer diagnosis. Int J Mol Sci.
22:86612021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dalli A, Selimoglu Sen H, Coskunsel M,
Komek H, Abakay O, Sergi C and Cetin Tanrikulu A: Diagnostic value
of PET/CT in differentiating benign from malignant solitary
pulmonary nodules. J BUON. 18:935–941. 2013.
|
|
11
|
Khalil A, Majlath M, Gounant V, Hess A,
Laissy JP and Debray MP: Contribution of magnetic resonance imaging
in lung cancer imaging. Diagn Interv Imaging. 97:991–1002. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Periaswamy G, Arunachalam VK,
Varatharajaperumal R, Kalyan G, Selvaraj R, Mehta P and Cherian M:
Comparison of ultrashort TE lung MRI and HRCT lungs for detection
of pulmonary nodules in oncology patients. Indian J Radiol Imaging.
32:497–504. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang Y, Guan S, Ou Z, Li W, Yan L and Situ
B: Advances in AI-based cancer cytopathology. Interdiscip Med.
1:e202300132023. View Article : Google Scholar
|
|
14
|
Li Y, Wu X, Yang P, Jiang G and Luo Y:
Machine learning for lung cancer diagnosis, treatment, and
prognosis. Genomics Proteomics Bioinformatics. 20:850–866. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
AbdulJabbar K, Raza SEA, Rosenthal R,
Jamal-Hanjani M, Veeriah S, Akarca A, Lund T, Moore DA, Salgado R,
Al Bakir M, et al: Geospatial immune variability illuminates
differential evolution of lung adenocarcinoma. Nat Med.
26:1054–1062. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Coudray N, Ocampo PS, Sakellaropoulos T,
Narula N, Snuderl M, Fenyö D, Moreira AL, Razavian N and Tsirigos
A: Classification and mutation prediction from non-small cell lung
cancer histopathology images using deep learning. Nat Med.
24:1559–1567. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li W, Liu JB, Hou LK, Yu F, Zhang J, Wu W,
Tang XM, Sun F, Lu HM, Deng J, et al: Liquid biopsy in lung cancer:
Significance in diagnostics, prediction, and treatment monitoring.
Mol Cancer. 21:252022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Levy B, Hu ZI, Cordova KN, Close S, Lee K
and Becker D: Clinical utility of liquid diagnostic platforms in
non-small cell lung cancer. Oncologist. 21:1121–1130. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zheng H, Wu X, Yin J, Wang S, Li Z and You
C: Clinical applications of liquid biopsies for early lung cancer
detection. Am J Cancer Res. 9:2567–2579. 2019.
|
|
20
|
Bao H, Min L, Bu F, Wang S and Meng J:
Recent advances of liquid biopsy: Interdisciplinary strategies
toward clinical decision-making. Interdiscip Med. 1:e202300212023.
View Article : Google Scholar
|
|
21
|
Zhu Y, Li W, Lan F, Chen S, Chen X, Zhang
X, Yan X and Zhang Y: DNA nanotechnology in tumor liquid biopsy:
Enrichment and determination of circulating biomarkers. Interdiscip
Med. 2:e202300432024. View Article : Google Scholar
|
|
22
|
El Andaloussi S, Mäger I, Breakefield XO
and Wood MJA: Extracellular vesicles: Biology and emerging
therapeutic opportunities. Nat Rev Drug Discov. 12:347–357. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen SW, Zhu SQ, Pei X, Qiu BQ, Xiong D,
Long X, Lin K, Lu F, Xu JJ and Wu YB: Cancer cell-derived exosomal
circUSP7 induces CD8+ T cell dysfunction and anti-PD1
resistance by regulating the miR-934/SHP2 axis in NSCLC. Mol
Cancer. 20:1442021. View Article : Google Scholar
|
|
24
|
You J, Li M, Cao LM, Gu QH, Deng PB, Tan Y
and Hu CP: Snail1-dependent cancer-associated fibroblasts induce
epithelial-mesenchymal transition in lung cancer cells via
exosomes. QJM. 112:581–590. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pavlova NN and Thompson CB: The emerging
hallmarks of cancer metabolism. Cell Metab. 23:27–47. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen W, Tang D, Lin J, Huang X, Lin S,
Shen G and Dai Y: Exosomal circSHKBP1 participates in non-small
cell lung cancer progression through PKM2-mediated glycolysis. Mol
Ther Oncolytics. 24:470–485. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu T, Han C, Fang P, Ma Z, Wang X, Chen
H, Wang S, Meng F, Wang C, Zhang E, et al: Cancer-associated
fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in
lung adenocarcinoma. J Hematol Oncol. 15:1412022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang D, Zhao C, Xu F, Zhang A, Jin M,
Zhang K, Liu L, Hua Q, Zhao J, Liu J, et al: Cisplatin-resistant
NSCLC cells induced by hypoxia transmit resistance to sensitive
cells through exosomal PKM2. Theranostics. 11:2860–2875. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu S, Luo M, To KKW, Zhang J, Su C, Zhang
H, An S, Wang F, Chen D and Fu L: Intercellular transfer of
exosomal wild type EGFR triggers osimertinib resistance in
non-small cell lung cancer. Mol Cancer. 20:172021. View Article : Google Scholar :
|
|
30
|
Zhang Q, Zheng K, Gao Y, Zhao S, Zhao Y,
Li W, Nan Y, Li Z, Liu W, Wang X, et al: Plasma exosomal miR-1290
and miR-29c-3p as diagnostic biomarkers for lung cancer. Heliyon.
9:e210592023. View Article : Google Scholar :
|
|
31
|
Gao S, Guo W, Liu T, Liang N, Ma Q, Gao Y,
Tan F, Xue Q and He J: Plasma extracellular vesicle microRNA
profiling and the identification of a diagnostic signature for
stage I lung adenocarcinoma. Cancer Sci. 113:648–659. 2022.
View Article : Google Scholar
|
|
32
|
Sun S, Chen H, Xu C, Zhang Y, Zhang Q,
Chen L, Ding Q and Deng Z: Exosomal miR-106b serves as a novel
marker for lung cancer and promotes cancer metastasis via targeting
PTEN. Life Sci. 244:1172972020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Open Biology Editorial Team: Retraction
'Reduced miR-125a-5p level in non-small-cell lung cancer is
associated with tumour progression'. Open Biol. 10:2002052020.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhong L, Sun S, Shi J, Cao F, Han X and
Chen Z: MicroRNA-125a-5p plays a role as a tumor suppressor in lung
carcinoma cells by directly targeting STAT3. Tumour Biol.
39:10104283176975792017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ye P, Lv X, Aizemaiti R, Cheng J, Xia P
and Di M: H3K27acactivated LINC00519 promotes lung squamous cell
carcinoma progression by targeting miR-450b-5p/miR-515-5p/YAP1
axis. Cell Prolif. 53:e127972020. View Article : Google Scholar
|
|
36
|
Yang G, Wang T, Qu X, Chen S, Han Z, Chen
S, Chen M, Lin J, Yu S, Gao L, et al: Exosomal miR-21/Let-7a ratio
distinguishes non-small cell lung cancer from benign pulmonary
diseases. Asia Pac J Clin Oncol. 16:280–286. 2020. View Article : Google Scholar
|
|
37
|
Zhong Y, Ding X, Bian Y, Wang J, Zhou W,
Wang X, Li P, Shen Y, Wang JJ, Li J, et al: Discovery and
validation of extracellular vesicle-associated miRNAs as
noninvasive detection biomarkers for early-stage non-small-cell
lung cancer. Mol Oncol. 15:2439–2452. 2021. View Article : Google Scholar :
|
|
38
|
Tang CP, Zhou HJ, Qin J, Luo Y and Zhang
T: MicroRNA-520c-3p negatively regulates EMT by targeting IL-8 to
suppress the invasion and migration of breast cancer. Oncol Rep.
38:3144–3152. 2017. View Article : Google Scholar
|
|
39
|
Gulhane P and Singh S: MicroRNA-520c-3p
impacts sphingolipid metabolism mediating PI3K/AKT signaling in
NSCLC: Systems perspective. J Cell Biochem. 123:1827–1840. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu X, Lu X, Sun J and Shu Y: microRNA
expression profiling of side population cells in human lung cancer
and preliminary analysis. Zhongguo Fei Ai Za Zhi. 13:665–669.
2010.In Chinese.
|
|
41
|
Squadrito ML, Baer C, Burdet F, Maderna C,
Gilfillan GD, Lyle R, Ibberson M and De Palma M: Endogenous RNAs
modulate microRNA sorting to exosomes and transfer to acceptor
cells. Cell Rep. 8:1432–1446. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Qi Y, Jin C, Qiu W, Zhao R, Wang S, Li B,
Zhang Z, Guo Q, Zhang S, Gao Z, et al: The dual role of glioma
exosomal microRNAs: Glioma eliminates tumor suppressor miR-1298-5p
via exosomes to promote immunosuppressive effects of MDSCs. Cell
Death Dis. 13:4262022. View Article : Google Scholar :
|
|
43
|
Chen X, Yu L, Hao K, Yin X, Tu M, Cai L,
Zhang L, Pan X, Gao Q and Huang Y: Fucosylated exosomal miRNAs as
promising biomarkers for the diagnosis of early lung
adenocarcinoma. Front Oncol. 12:9351842022. View Article : Google Scholar :
|
|
44
|
Hu Y, Bai J, Zhou D, Zhang L, Chen X, Chen
L, Liu Y, Zhang B, Li H and Yin C: The miR-4732-5p/XPR1 axis
suppresses the invasion, metastasis, and epithelial-mesenchymal
transition of lung adenocarcinoma via the PI3K/Akt/GSK3β/Snail
pathway. Mol Omics. 18:417–429. 2022. View Article : Google Scholar
|
|
45
|
Shen YY, Cui JY, Yuan J and Wang X:
MiR-451a suppressed cell migration and invasion in non-small cell
lung cancer through targeting ATF2. Eur Rev Med Pharmacol Sci.
22:5554–5561. 2018.PubMed/NCBI
|
|
46
|
Ding L, Tian W, Zhang H, Li W, Ji C, Wang
Y and Li Y: MicroRNA-486-5p suppresses lung cancer via
downregulating mTOR signaling in vitro and in vivo. Front Oncol.
11:6552362021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zheng X, Zhang Y, Wu S, Jiang B and Liu Y:
MiR-139-3p targets CHEK1 modulating DNA repair and cell viability
in lung squamous carcinoma cells. Mol Biotechnol. 64:832–840. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zheng B, Peng M, Gong J, Li C, Cheng H, Li
Y and Tang Y: Circulating exosomal microRNA-4497 as a potential
biomarker for metastasis and prognosis in non-small-cell lung
cancer. Exp Biol Med (Maywood). 248:1403–1413. 2023. View Article : Google Scholar
|
|
49
|
Jin X, Chen Y, Chen H, Fei S, Chen D, Cai
X, Liu L, Lin B, Su H, Zhao L, et al: Evaluation of tumor-derived
exosomal miRNA as potential diagnostic biomarkers for early-stage
non-small cell lung cancer using next-generation sequencing. Clin
Cancer Res. 23:5311–5319. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Li Y, Zhao J, Yu S, Wang Z, He X, Su Y,
Guo T, Sheng H, Chen J, Zheng Q, et al: Extracellular vesicles long
RNA sequencing reveals abundant mRNA, circRNA, and lncRNA in human
blood as potential biomarkers for cancer diagnosis. Clin Chem.
65:798–808. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang Y, Liu W, Zhang H, Sun B, Chen T, Hu
M, Zhou H, Cao Y, Han B and Wu L: Extracellular vesicle long RNA
markers of early-stage lung adenocarcinoma. Int J Cancer.
152:1490–1500. 2023. View Article : Google Scholar
|
|
52
|
Wang N, Yao C, Luo C, Liu S, Wu L, Hu W,
Zhang Q, Rong Y, Yuan C and Wang F: Integrated plasma and exosome
long noncoding RNA profiling is promising for diagnosing non-small
cell lung cancer. Clin Chem Lab Med. 61:2216–2228. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Min L, Zhu T, Lv B, An T, Zhang Q, Shang
Y, Yu Z, Zheng L and Wang Q: Exosomal LncRNA RP5-977B1 as a novel
minimally invasive biomarker for diagnosis and prognosis in
non-small cell lung cancer. Int J Clin Oncol. 27:1013–1024. 2022.
View Article : Google Scholar
|
|
54
|
Li C, Lv Y, Shao C, Chen C, Zhang T, Wei
Y, Fan H, Lv T, Liu H and Song Y: Tumor-derived exosomal lncRNA
GAS5 as a biomarker for early-stage non-small-cell lung cancer
diagnosis. J Cell Physiol. 234:20721–20727. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wang H, Meyer CA, Fei T, Wang G, Zhang F
and Liu XS: A systematic approach identifies FOXA1 as a key factor
in the loss of epithelial traits during the
epithelial-to-mesenchymal transition in lung cancer. BMC Genomics.
14:6802013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kuang M, Peng Y, Tao X, Zhou Z, Mao H,
Zhuge L, Sun Y and Zhang H: FGB and FGG derived from plasma
exosomes as potential biomarkers to distinguish benign from
malignant pulmonary nodules. Clin Exp Med. 19:557–564. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chang W, Zhu J, Yang D, Shang A, Sun Z,
Quan W and Li D: Plasma versican and plasma exosomal versican as
potential diagnostic markers for non-small cell lung cancer. Respir
Res. 24:1402023. View Article : Google Scholar
|
|
58
|
Yang P, Zhang Y, Zhang R, Wang Y, Zhu S,
Peng X, Zeng Y, Yang B, Pan M, Gong J and Ba H: Plasma-derived
exosomal immunoglobulins IGHV4-4 and IGLV1-40 as new non-small cell
lung cancer biomarkers. Am J Cancer Res. 13:1923–1937.
2023.PubMed/NCBI
|
|
59
|
Luo B, Que Z, Lu X, Qi D, Qiao Z, Yang Y,
Qian F, Jiang Y, Li Y, Ke R, et al: Identification of exosome
protein panels as predictive biomarkers for non-small cell lung
cancer. Biol Proced Online. 25:292023. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Hoshino A, Kim HS, Bojmar L, Gyan KE,
Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H,
Heissel S, et al: Extracellular vesicle and particle biomarkers
define multiple human cancers. Cell. 182:1044–1061.e18. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
An T, Qin S, Sun D, Huang Y, Hu Y, Li S,
Zhang H, Li B, Situ B, Lie L, et al: Unique protein profiles of
extracellular vesicles as diagnostic biomarkers for early and
advanced non-small cell lung cancer. Proteomics. 19:e18001602019.
View Article : Google Scholar
|
|
62
|
Schlesinger M: Role of platelets and
platelet receptors in cancer metastasis. J Hematol Oncol.
11:1252018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Denis MM, Tolley ND, Bunting M, Schwertz
H, Jiang H, Lindemann S, Yost CC, Rubner FJ, Albertine KH, Swoboda
KJ, et al: Escaping the nuclear confines: Signal-dependent pre-mRNA
splicing in anucleate platelets. Cell. 122:379–391. 2005.
View Article : Google Scholar
|
|
64
|
Li X, Liu L and Song X, Wang K, Niu L, Xie
L and Song X: TEP linc-GTF2H2-1, RP3-466P17.2, and lnc-ST8SIA4-12
as novel biomarkers for lung cancer diagnosis and progression
prediction. J Cancer Res Clin Oncol. 147:1609–1622. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Xing S, Zeng T, Xue N, He Y, Lai YZ, Li
HL, Huang Q, Chen SL and Liu WL: Development and validation of
tumor-educated blood platelets integrin alpha 2b (ITGA2B) RNA for
diagnosis and prognosis of non-small-cell lung cancer through
RNA-seq. Int J Biol Sci. 15:1977–1992. 2019. View Article : Google Scholar
|
|
66
|
Tian T, Lu J, Zhao W, Wang Z, Xu H, Ding
Y, Guo W, Qin P, Zhu W, Song C, et al: Associations of systemic
inflammation markers with identification of pulmonary nodule and
incident lung cancer in Chinese population. Cancer Med.
11:2482–2491. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zu R, Wu L, Zhou R, Wen X, Cao B, Liu S,
Yang G, Leng P, Li Y, Zhang L, et al: A new classifier constructed
with platelet features for malignant and benign pulmonary nodules
based on prospective real-world data. J Cancer. 13:2515–2527. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Lu TX and Rothenberg ME: MicroRNA. J
Allergy Clin Immunol. 141:1202–1207. 2018. View Article : Google Scholar :
|
|
69
|
He B, Zhao Z, Cai Q, Zhang Y, Zhang P, Shi
S, Xie H, Peng X, Yin W, Tao Y and Wang X: miRNA-based biomarkers,
therapies, and resistance in Cancer. Int J Biol Sci. 16:2628–2647.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Ge N, Mao C, Yang Q, Han B, Wang Y, Xu L,
Yang X, Jiao W and Li C: Single nucleotide polymorphism rs3746444
in miR-499a affects susceptibility to non-small cell lung carcinoma
by regulating the expression of CD200. Int J Mol Med. 43:2221–2229.
2019.PubMed/NCBI
|
|
71
|
Xi KX, Zhang XW, Yu XY, Wang WD, Xi KX,
Chen YQ, Wen YS and Zhang LJ: The role of plasma miRNAs in the
diagnosis of pulmonary nodules. J Thorac Dis. 10:4032–4041. 2018.
View Article : Google Scholar
|
|
72
|
He Y, Ren S, Wang Y, Li X, Zhou C and
Hirsch FR: Serum microRNAs improving the diagnostic accuracy in
lung cancer presenting with pulmonary nodules. J Thorac Dis.
10:5080–5085. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Shen J, Liu Z, Todd NW, Zhang H, Liao J,
Yu L, Guarnera MA, Li R, Cai L, Zhan M and Jiang F: Diagnosis of
lung cancer in individuals with solitary pulmonary nodules by
plasma microRNA biomarkers. BMC Cancer. 11:3742011. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Fan L, Sha J, Teng J, Li D, Wang C, Xia Q,
Chen H, Su B and Qi H: Evaluation of serum paired MicroRNA ratios
for differential diagnosis of non-small cell lung cancer and benign
pulmonary diseases. Mol Diagn Ther. 22:493–502. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Huang Z, Wang Z, Xia H, Ge Z, Yu L, Li J,
Bao H, Liang Z, Cui Y and Xu Y: Long noncoding RNA HAND2-AS1: A
crucial regulator of malignancy. Clin Chim Acta. 539:162–169. 2023.
View Article : Google Scholar
|
|
76
|
Karger A, Mansouri S, Leisegang MS,
Weigert A, Günther S, Kuenne C, Wittig I, Zukunft S, Klatt S,
Aliraj B, et al: ADPGK-AS1 long noncoding RNA switches macrophage
metabolic and phenotypic state to promote lung cancer growth. EMBO
J. 42:e1116202023. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Chen X, Zhu X, Yan W, Wang L, Xue D, Zhu
S, Pan J, Li Y, Zhao Q and Han D: Serum lncRNA THRIL predicts
benign and malignant pulmonary nodules and promotes the progression
of pulmonary malignancies. BMC Cancer. 23:7552023. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Jiang N, Meng X, Mi H, Chi Y, Li S, Jin Z,
Tian H, He J, Shen W, Tian H, et al: Circulating lncRNA XLOC_009167
serves as a diagnostic biomarker to predict lung cancer. Clin Chim
Acta. 486:26–33. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Fackche NT, Mei Y, Ito T, Garner M and
Brock M: Abstract 1822: A mitochondrial pfeRNA associates with far
upstream element binding protein 1 (FUBP1) to promote lung
adenocarcinoma tumorigenesis. Cancer Res. 79(Suppl 13): S18222019.
View Article : Google Scholar
|
|
80
|
Brock M and Mei Y: Protein functional
effector sncRNAs (pfeRNAs) in lung cancer. Cancer Lett.
403:138–143. 2017. View Article : Google Scholar
|
|
81
|
Liu W, Wang Y, Huang H, Fackche N, Rodgers
K, Lee B, Nizam W, Khan H, Lu Z, Kong X, et al: A cost-effective
and non-invasive pfeRNA-based test differentiates benign and
suspicious pulmonary nodules from malignant ones. Noncoding RNA.
7:802021.
|
|
82
|
Ponomaryova AA, Rykova EY, Solovyova AI,
Tarasova AS, Kostromitsky DN, Dobrodeev AY, Afanasiev SA and
Cherdyntseva NV: Genomic and transcriptomic research in the
discovery and application of colorectal cancer circulating markers.
Int J Mol Sci. 24:124072023. View Article : Google Scholar :
|
|
83
|
Schwarzenbach H, Hoon DSB and Pantel K:
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev
Cancer. 11:426–437. 2011. View Article : Google Scholar
|
|
84
|
Jiang N, Zhou J, Zhang W, Li P, Liu Y, Shi
H, Zhang C, Wang Y, Zhou C, Peng C, et al: RNF213 gene mutation in
circulating tumor DNA detected by targeted next-generation
sequencing in the assisted discrimination of early-stage lung
cancer from pulmonary nodules. Thorac Cancer. 12:181–193. 2021.
View Article : Google Scholar
|
|
85
|
Peng M, Xie Y, Li X, Qian Y, Tu X, Yao X,
Cheng F, Xu F, Kong D, He B, et al: Resectable lung lesions
malignancy assessment and cancer detection by ultra-deep sequencing
of targeted gene mutations in plasma cell-free DNA. J Med Genet.
56:647–653. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Hung CS, Wang SC, Yen YT, Lee TH, Wen WC
and Lin RK: Hypermethylation of CCND2 in lung and breast cancer is
a potential biomarker and drug target. Int J Mol Sci. 19:30962018.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Liang W, Zhao Y, Huang W, Gao Y, Xu W, Tao
J, Yang M, Li L, Ping W, Shen H, et al: Non-invasive diagnosis of
early-stage lung cancer using high-throughput targeted DNA
methylation sequencing of circulating tumor DNA (ctDNA).
Theranostics. 9:2056–2070. 2019. View Article : Google Scholar :
|
|
88
|
Fang Y, Qu Y, Ji L, Sun H, Li J, Zhao Y,
Liang F, Wang Z, Su J, Liu J, et al: Novel blood-based FUT7 DNA
methylation is associated with lung cancer: Especially for lung
squamous cell carcinoma. Clin Epigenetics. 14:1672022. View Article : Google Scholar
|
|
89
|
Crowley E, Di Nicolantonio F, Loupakis F
and Bardelli A: Liquid biopsy: Monitoring cancer-genetics in the
blood. Nat Rev Clin Oncol. 10:472–484. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Chen C, Huang X, Yin W, Peng M, Wu F, Wu
X, Tang J, Chen M, Wang X, Hulbert A, et al: Ultrasensitive DNA
hypermethylation detection using plasma for early detection of
NSCLC: A study in Chinese patients with very small nodules. Clin
Epigenetics. 12:392020. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Zhao Y, O'Keefe CM, Hsieh K, Cope L, Joyce
SC, Pisanic TR, Herman JG and Wang TH: Multiplex digital
methylation-specific PCR for noninvasive screening of lung cancer.
Adv Sci (Weinh). 10:e22065182023. View Article : Google Scholar
|
|
92
|
Wang Z, Xie K, Zhu G, Ma C, Cheng C, Li Y,
Xiao X, Li C, Tang J, Wang H, et al: Early detection and
stratification of lung cancer aided by a cost-effective assay
targeting circulating tumor DNA (ctDNA) methylation. Respir Res.
24:1632023. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Xing W, Sun H, Yan C, Zhao C, Wang D, Li M
and Ma J: A prediction model based on DNA methylation biomarkers
and radiological characteristics for identifying malignant from
benign pulmonary nodules. BMC Cancer. 21:2632021. View Article : Google Scholar
|
|
94
|
He J, Wang B, Tao J, Liu Q, Peng M, Xiong
S, Li J, Cheng B, Li C, Jiang S, et al: Accurate classification of
pulmonary nodules by a combined model of clinical, imaging, and
cell-free DNA methylation biomarkers: A model development and
external validation study. Lancet Digit Health. 5:e647–e656. 2023.
View Article : Google Scholar
|
|
95
|
Seijo LM, Peled N, Ajona D, Boeri M, Field
JK, Sozzi G, Pio R, Zulueta JJ, Spira A, Massion PP, et al:
Biomarkers in lung cancer screening: achievements, promises, and
challenges. J Thorac Oncol. 14:343–357. 2019. View Article : Google Scholar
|
|
96
|
Zhang X, Liu M, Zhang X, Wang Y and Dai L:
Autoantibodies to tumor-associated antigens in lung cancer
diagnosis. Adv Clin Chem. 103:1–45. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Lastwika KJ, Kargl J, Zhang Y, Zhu X, Lo
E, Shelley D, Ladd JJ, Wu W, Kinahan P, Pipavath SNJ, et al:
Tumor-derived autoantibodies identify malignant pulmonary nodules.
Am J Respir Crit Care Med. 199:1257–1266. 2019. View Article : Google Scholar :
|
|
98
|
Xu L, Chang N, Yang T, Lang Y, Zhang Y,
Che Y, Xi H, Zhang W, Song Q, Zhou Y, et al: Development of
diagnosis model for early lung nodules based on a seven
autoantibodies panel and imaging features. Front Oncol.
12:8835432022. View Article : Google Scholar
|
|
99
|
Auger C, Moudgalya H, Neely MR, Stephan
JT, Tarhoni I, Gerard D, Basu S, Fhied CL, Abdelkader A, Vargas M,
et al: Development of a novel circulating autoantibody biomarker
panel for the identification of patients with 'actionable'
pulmonary nodules. Cancers (Basel). 15:22592023. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Shome M, Gao W, Engelbrektson A, Song L,
Williams S, Murugan V, Park JG, Chung Y, LaBaer J and Qiu J:
Comparative microbiomics analysis of antimicrobial antibody
response between patients with lung cancer and control subjects
with benign pulmonary nodules. Cancer Epidemiol Biomarkers Prev.
32:496–504. 2023. View Article : Google Scholar
|
|
101
|
Sina AAI, Vaidyanathan R, Dey S,
Carrascosa LG, Shiddiky MJA and Trau M: Real time and label free
profiling of clinically relevant exosomes. Sci Rep. 6:304602016.
View Article : Google Scholar
|
|
102
|
Fang S, Tian H, Li X, Jin D, Li X, Kong J,
Yang C, Yang X, Lu Y, Luo Y, et al: Clinical application of a
microfluidic chip for immunocapture and quantification of
circulating exosomes to assist breast cancer diagnosis and
molecular classification. PLoS One. 12:e01750502017. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Morales-Pacheco M, Valenzuela-Mayen M,
Gonzalez-Alatriste AM, Mendoza-Almanza G, Cortés-Ramírez SA,
Losada-García A, Rodríguez-Martínez G, González-Ramírez I,
Maldonado-Lagunas V, Vazquez-Santillan K, et al: The role of
platelets in cancer: From their influence on tumor progression to
their potential use in liquid biopsy. Biomark Res. 13:272025.
View Article : Google Scholar
|
|
104
|
Didychuk AL, Butcher SE and Brow DA: The
life of U6 small nuclear RNA, from cradle to grave. RNA.
24:437–460. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Najafi S, Asemani Y, Majidpoor J, Mahmoudi
R, Aghaei-Zarch SM and Mortezaee K: Tumor-educated platelets. Clin
Chim Acta. 552:1176902024. View Article : Google Scholar
|
|
106
|
Khan J, Lieberman JA and Lockwood CM:
Variability in, variability out: best practice recommendations to
standardize pre-analytical variables in the detection of
circulating and tissue microRNAs. Clin Chem Lab Med. 55:608–621.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Sánchez-Herrero E, Provencio M and Romero
A: Clinical utility of liquid biopsy for the diagnosis and
monitoring of EML4-ALK NSCLC patients. Adv Lab Med.
1:201900192020.
|
|
108
|
Lennon AM, Buchanan AH, Kinde I, Warren A,
Honushefsky A, Cohain AT, Ledbetter DH, Sanfilippo F, Sheridan K,
Rosica D, et al: Feasibility of blood testing combined with PET-CT
to screen for cancer and guide intervention. Science.
369:eabb96012020. View Article : Google Scholar :
|
|
109
|
Cescon DW, Bratman SV, Chan SM and Siu LL:
Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer.
1:276–290. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Chaudhuri AA, Chabon JJ, Lovejoy AF,
Newman AM, Stehr H, Azad TD, Khodadoust MS, Esfahani MS, Liu CL,
Zhou L, et al: Early detection of molecular residual disease in
localized lung cancer by circulating tumor DNA profiling. Cancer
Discov. 7:1394–1403. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Fagery M, Khorshidi HA, Wong SQ, Vu M and
Ijzerman M: Health economic evidence and modeling challenges for
liquid biopsy assays in cancer management: A systematic literature
review. PharmacoEconomics. 41:1229–1248. 2023. View Article : Google Scholar :
|
|
112
|
Kammer MN, Lakhani DA, Balar AB, Antic SL,
Kussrow AK, Webster RL, Mahapatra S, Barad U, Shah C, Atwater T, et
al: Integrated biomarkers for the management of indeterminate
pulmonary nodules. Am J Respir Crit Care Med. 204:1306–1316. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Siravegna G, Marsoni S, Siena S and
Bardelli A: Integrating liquid biopsies into the management of
cancer. Nat Rev Clin Oncol. 14:531–548. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Jamal-Hanjani M, Wilson GA, McGranahan N,
Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R,
Rosenthal R, et al: Tracking the evolution of non-small-cell lung
cancer. N Engl J Med. 376:2109–2121. 2017. View Article : Google Scholar
|
|
115
|
Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim
HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WSME, et
al: Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung
cancer. N Engl J Med. 376:629–640. 2017. View Article : Google Scholar
|
|
116
|
Gandara DR, Paul SM, Kowanetz M,
Schleifman E, Zou W, Li Y, Rittmeyer A, Fehrenbacher L, Otto G,
Malboeuf C, et al: Blood-based tumor mutational burden as a
predictor of clinical benefit in non-small-cell lung cancer
patients treated with atezolizumab. Nat Med. 24:1441–1448. 2018.
View Article : Google Scholar
|
|
117
|
Oxnard GR, Paweletz CP, Kuang Y, Mach SL,
O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P,
Jackman DM and Jänne PA: Noninvasive detection of response and
resistance in EGFR-mutant lung cancer using quantitative
next-generation genotyping of cell-free plasma DNA. Clin Cancer
Res. 20:1698–1705. 2014. View Article : Google Scholar
|
|
118
|
Rolfo C, Mack P, Scagliotti GV, Aggarwal
C, Arcila ME, Barlesi F, Bivona T, Diehn M, Dive C, Dziadziuszko R,
et al: Liquid biopsy for advanced NSCLC: A consensus statement from
the international association for the study of lung cancer. J
Thorac Oncol. 16:1647–1662. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Pennell NA, Mutebi A, Zhou ZY, Ricculli
ML, Tang W, Wang H, Guerin A, Arnhart T, Dalal A, Sasane M, et al:
Economic impact of next-generation sequencing versus single-gene
testing to detect genomic alterations in metastatic non-small-cell
lung cancer using a decision analytic model. JCO Precis Oncol.
3:1–9. 2019. View Article : Google Scholar
|
|
120
|
Leighl NB, Page RD, Raymond VM, Daniel DB,
Divers SG, Reckamp KL, Villalona-Calero MA, Dix D, Odegaard JI,
Lanman RB and Papadimitrakopoulou VA: Clinical utility of
comprehensive cell-free DNA analysis to identify genomic biomarkers
in patients with newly diagnosed metastatic non-small cell lung
cancer. Clin Cancer Res. 25:4691–4700. 2019. View Article : Google Scholar
|
|
121
|
Xie H, Jia Y and Liu S: Integration of
artificial intelligence in clinical laboratory medicine:
Advancements and challenges. Interdiscip Med. 2:e202300562024.
View Article : Google Scholar
|
